<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04893538</url>
  </required_header>
  <id_info>
    <org_study_id>Lymphopenia and Hodgkin</org_study_id>
    <nct_id>NCT04893538</nct_id>
  </id_info>
  <brief_title>Prognostic Value Of Lymphocyte Count and Lymphocyte/ Monocyte Ratio in Patients With Hodgkin's Lymphoma</brief_title>
  <official_title>Prognostic Value Of Lymphocyte Count and Lymphocyte/ Monocyte Ratio in Patients With Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tishreen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tishreen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the utility of using Absolute Lymphocyte count, Absolute Monocyte&#xD;
      count and Lymphocyte/Monocyte Ratio at diagnosis in Hodgkin's Lymphoma as a prognostic&#xD;
      predictor of therapeutic response, overall survival and progression free survival&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hodgkin's Lymphoma has a high cure rate even if patients do not complete their treatment,&#xD;
      this proposes that some patients may experience overtreatment and that would have negative&#xD;
      effects (such as cardiac toxicity, sterility, secondary malignancies...) which makes it&#xD;
      imperative to search for prognostic predictor suitable for all stages of disease, knowing&#xD;
      that the International Prognostic Score &quot;IPS&quot; is restricted to advanced stages of the&#xD;
      disease.&#xD;
&#xD;
      Absolute Lymphocyte count reflects the immune status of the individuals. It has been shown&#xD;
      that an individual's immune status controls the extent of his response treatment, overall&#xD;
      survival and his progression free survival because of the role that Lymphocytes play in&#xD;
      suppressing and eliminating tumor cells.&#xD;
&#xD;
      Tumor-Associated Macrophages &quot;TAMs&quot; have been shown to play a role in tumor growth and&#xD;
      development. Also, it has been shown that an increase in peripheral Monocyte count is&#xD;
      associated with an increase in TAMs, so that the Monocyte count may constitute an important&#xD;
      prognostic predictor.&#xD;
&#xD;
      Combining the Lymphocyte count and the Monocyte count into one index may be better for&#xD;
      estimating the prognosis.&#xD;
&#xD;
      The aim of this study is to determine the prognostic significance of Absolute Lymphocyte&#xD;
      count &quot;ALC&quot;, Absolute Monocyte count&quot;AMC&quot;, Lymphocyte/Monocyte Ratio &quot;LMR&quot; at the cut-off&#xD;
      points: 1500 cells per microliter for ALC, 720 cells per microliter for AMC and 2.9 for LMR.&#xD;
&#xD;
      Investigators get these cut-off points by conducting a retrospective case-control study on&#xD;
      previous patients in Oncology Center, Tishreen Hospital, Syria in 2020.&#xD;
&#xD;
      This study will be prospective cohort :&#xD;
&#xD;
        1. participants will be divided into two subgroups (patients have ALC &gt;= 1500 cells per&#xD;
           microliter and who have ALC &lt; 1500 cells per microliter). Those two subgroups will be&#xD;
           similar in terms of other prognostic factors.&#xD;
&#xD;
        2. the same participants will be also divided into another two subgroups (who have AMC &lt;720&#xD;
           cells per microliter and who have AMC &gt;=720 cells per microliter) and Those two&#xD;
           subgroups will be similar in terms of other prognostic factors.&#xD;
&#xD;
        3. Finally the same participants will be divided into two subgroups (who have LMR &gt;= 2.9&#xD;
           and who have LMR &lt; 2.9) and Those two subgroups will be similar in terms of other&#xD;
           prognostic factors.&#xD;
&#xD;
      Then Investigators will monitor the therapeutic response, overall survival and progression&#xD;
      free survival for 18 months for each subgroup and compare these indexes with the &quot;IPS&quot; to&#xD;
      determine the effectiveness of each of them in each stage of the disease&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 21, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>18 Months</target_duration>
  <primary_outcome>
    <measure>Therapeutic response</measure>
    <time_frame>6 months</time_frame>
    <description>Achieve complete remission after completing the prescribed treatment plan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>18 months</time_frame>
    <description>The occurrence of death after acceptance to study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>18 months</time_frame>
    <description>The occurrence of relapse after acceptance to study</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <description>First analysis: Patients with high Lymphocyte count Second analysis: Patients with low monocyte count Third analysis: Patients with high Lymphocyte/monocyte ratio</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <description>First analysis: Patients with low Lymphocyte count Second analysis: Patients with high monocyte count Third analysis: Patients with low Lymphocyte/monocyte ratio</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>First analysis: Lymphocyte count &gt; or = 1500 cells per microlitre, second analysis: Monocyte count &lt; 720 cells per microlitre and third analysis: Lymphocyte/Monocyte ratio &gt; or = 2.9</intervention_name>
    <description>Intravenous blood sampling from participants for complete blood count to obtain Lymphocyte count, Monocyte count and Lymphocyte/Monocyte Ratio</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>First analysis: Lymphocyte count &lt; 1500 cells per microlitre, second analysis: Monocyte count &gt; or = 720 cells per microlitre and third analysis: Lymphocyte/Monocyte ratio &lt; 2.9</intervention_name>
    <description>Intravenous blood sampling from participants for complete blood count to obtain Lymphocyte count, Monocyte count and Lymphocyte/Monocyte Ratio</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients newly diagnosed with Hodgkin's lymphoma at the Oncology Center of Tishreen&#xD;
        University Hospital who have not yet received treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed patients with Hodgkin's Lymphoma who have not yet received treatment&#xD;
&#xD;
          -  Ages over 15 years old&#xD;
&#xD;
          -  Signed informed consent before registration in study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have already received treatment&#xD;
&#xD;
          -  Patients with a previous history of malignancy&#xD;
&#xD;
          -  Patients with autoimmune diseases&#xD;
&#xD;
          -  Patients with primary immunodeficiency&#xD;
&#xD;
          -  AIDS patients&#xD;
&#xD;
          -  Patients with acute or chronic infections&#xD;
&#xD;
          -  Patients treated with drugs that affect the result of the analysis (Corticosteroids,&#xD;
             Immunosuppressants, Li)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>FIRAS Hussain, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Tishreen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hassan Khalil, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tishreen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hassan Khalil, Dr.</last_name>
    <phone>00963992869604</phone>
    <email>hsnkhal@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tishreen University</name>
      <address>
        <city>Latakia</city>
        <country>Syrian Arab Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hassan Khalil, Dr.</last_name>
      <phone>00963992869604</phone>
      <email>hsnkhal@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Syrian Arab Republic</country>
  </location_countries>
  <reference>
    <citation>Hancock BW, Dunsmore IR, Swan HT. Lymphopenia: a bad prognostic factor in Hodgkin's disease. Scand J Haematol. 1982 Sep;29(3):193-9.</citation>
    <PMID>7146822</PMID>
  </reference>
  <reference>
    <citation>Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998 Nov 19;339(21):1506-14.</citation>
    <PMID>9819449</PMID>
  </reference>
  <reference>
    <citation>Ayoub JP, Palmer JL, Huh Y, Cabanillas F, Younes A. Therapeutic and prognostic implications of peripheral blood lymphopenia in patients with Hodgkin's disease. Leuk Lymphoma. 1999 Aug;34(5-6):519-27.</citation>
    <PMID>10492075</PMID>
  </reference>
  <reference>
    <citation>Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson C, Markovic SN. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica. 2012 Feb;97(2):262-9. doi: 10.3324/haematol.2011.050138. Epub 2011 Oct 11.</citation>
    <PMID>21993683</PMID>
  </reference>
  <reference>
    <citation>Koh YW, Kang HJ, Park C, Yoon DH, Kim S, Suh C, Go H, Kim JE, Kim CW, Huh J. The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin's lymphoma: correlation with tumor-associated macrophages. Oncologist. 2012;17(6):871-80. doi: 10.1634/theoncologist.2012-0034. Epub 2012 May 15.</citation>
    <PMID>22588324</PMID>
  </reference>
  <reference>
    <citation>Tadmor T, Polliack A. Lymphopenia a simple prognostic factor in lymphoma and other cancers: why not use it more as a guide? Leuk Lymphoma. 2010 Oct;51(10):1773-4. doi: 10.3109/10428194.2010.508825.</citation>
    <PMID>20849382</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphocyte count</keyword>
  <keyword>monocyte count</keyword>
  <keyword>Lymphocyte/monocyte Ratio</keyword>
  <keyword>Prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

